Identification of Metoprolol Tartrate-Derived Reactive Metabolites Possibly Correlated with Its Cytotoxicity

Xiaonan Li1, Gang Xing2, Xinxin Guo1

  • 1Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, P. R. China.

Insights

Metoprolol tartrate (MTA) can cause liver injury through reactive metabolites. This study identified these metabolites and a potential quinone methide intermediate, linking metabolic activation to MTA

Area of Science:

  • Pharmacology
  • Hepatology
  • Drug Metabolism

Background:

  • Metoprolol tartrate (MTA) is a selective β1-receptor antagonist used for cardiovascular diseases.
  • Hepatotoxicity from MTA has been reported, but the underlying mechanism remains unclear.

Purpose of the Study:

  • Identify reactive metabolites of MTA.
  • Determine the metabolic activation pathway of MTA.
  • Correlate MTA's metabolic activation with its cytotoxicity.

Main Methods:

  • Rat liver microsomal incubations with MTA, glutathione (GSH), and N-acetyl cysteine (NAC).
  • Detection of metabolites in hepatocytes, bile, and urine.
  • Assessment of MTA-induced cytotoxicity in cultured rat primary hepatocytes.
  • Use of a P450 enzyme inhibitor (aminobenzotriazole).

Main Results:

  • Three oxidative metabolites (M1-M3), a GSH conjugate (M4), and an NAC conjugate (M5) were identified.
  • M4 was found in hepatocytes and bile; M5 was found in urine.
  • A reactive quinone methide intermediate was proposed.
  • MTA induced significant cytotoxicity in hepatocytes, which was reduced by P450 inhibition.

Conclusions:

  • MTA undergoes metabolic activation to reactive intermediates.
  • These reactive metabolites are linked to MTA's cytotoxicity.
  • Understanding this mechanism may help predict or prevent MTA-induced liver injury.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...